Just like you.
Our focus and strategy are clear. In 2013 we plan to build on the growing awareness of the promise of regenerative medicine to make it the best year not only in this field but in the company’s history, as well. This year we hope to achieve a number of specific milestones, including:
Reverse stock split and up-listing of our stock to NASDAQ - FAIL
Completion of both of our Phase I trials for Stargardt’s Disease in the U.S. and Europe, and our Phase I trial for dry age-related macular degeneration (dry AMD) - FAIL
Sharing final Phase I trial results with our followers - FAIL
New developments involving our various initiatives in Europe - FAIL
Initiation of our Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program - FAIL
Initiation of three Phase II trials for SMD and dry AMD - FAIL
Initiation of clinical trial for myopia - FAIL
0 FOR 8.
From Chairman's Blog January 2013:
"You no doubt saw our announcement about New Scientist magazine’s coverage of our planned induced pluripotent stem cell-(iPSC) based clinical trial. Calling the trial “revolutionary,” the magazine included it as one of “10 ideas that will shape the year.” This followed on the Wall Street Journal’s exclusive story, reporting on our plans to start the process for regulatory approval of the trial."
What did you expect to be PR'd? You must know by now to add 6-12 months to anything Rabin promises, i.e. top line results.
That's interesting. I thought "Fast Track" was an FDA option, not NIH.
Elk - A/G will either have to settle for something significantly less than they want or expect to be residing in the appeals court(if they case doesn't get thrown out on the jurisdiction issue) for a very long time. The MAJOR issue is the SEC settlement which Rabin has been saying they are very close to settling since last year. In my mind, only horseshoes and hand grenades fit in the "close" category. Rabin's job, first and foremost, is to keep the company afloat in any fashion he can. He is a salesman that so far has been mostly sizzle and no steak. If he does not deliver a settlement and top-line results as promised by years end, the BOD needs to take action.